23:38:08 EDT Thu 15 Apr 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save

Q:FGEN - FIBROGEN INC - http://www.fibrogen.com23:38:08 EDT
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FGEN - Q1.019.10·19.500.119.30+0.040.21,785.534,60316,67819.36  19.99  19.10257.2088  18.1219:29:1113:4415 min RT 2¢

Recent Trades - Last 10 of 16678
Time ETExPriceChangeVolume
19:29:11Q19.25-0.011
19:13:42Q19.25-0.011
18:23:41Q19.25-0.011
18:19:54Q19.20-0.0650
18:19:22Q19.20-0.0631
18:18:23Q19.290.0314
18:17:56Q19.290.0310
18:16:33Q19.300.042
18:15:35Q19.300.042
18:11:32Q19.300.0415

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent BulletinsNews ReleasesIn The NewsOther
Date ETSymbolTypeHeadline
2021-04-15 13:44U:FGENNews ReleaseSHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2021-04-15 11:41U:FGENNews ReleaseKessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline for Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
2021-04-15 11:12U:FGENNews ReleaseFGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.
2021-04-15 07:00U:FGENNews ReleaseFibroGen Receives Rare Pediatric Disease Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2021-04-14 14:58U:FGENNews ReleaseFGEN CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces a Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.
2021-04-14 09:30U:FGENNews ReleaseSHAREHOLDER ALERT: FibroGen, Inc. (FGEN) Officers and Directors Under Investigation for False Statements and Insider Trading
2021-04-13 21:00U:FGENNews ReleaseFIBROGEN ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against FibroGen, Inc. and Encourages Investors to Contact the Firm
2021-04-13 21:00U:FGENNews ReleaseBREAKING NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important Deadline - FGEN
2021-04-13 20:37U:FGENNews ReleaseFIBROGEN SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against FibroGen, Inc. - FGEN
2021-04-13 15:00U:FGENNews ReleaseFGEN Investor Alert: Bronstein, Gewirtz & Grossman, LLC Notifies FibroGen, Inc. Shareholders of Class Action and Encourages Investors to Contact the Firm
2021-04-12 07:00U:FGENNews ReleaseFibroGen Receives Fast Track Designation from the U.S. FDA for Pamrevlumab for the Treatment of Duchenne Muscular Dystrophy
2021-04-09 13:51U:FGENNews ReleaseONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against FibroGen, Inc. and Encourages Investors with Losses of $100,000 to Contact the Firm
2021-04-08 14:51U:FGENNews ReleaseScott+Scott Attorneys at Law LLP Announces Investigation into FibroGen, Inc. (FGEN)
2021-04-08 09:36U:FGENNews ReleaseHAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors with Losses to Contact Its Attorneys Now, Company Admits to Manipulating Data for Anemia Drug
2021-04-08 04:30U:FGENNews ReleaseAdemi LLP Investigates Claims of Securities Fraud against FibroGen Inc.